Longboard Pharmaceuticals Inc logo

Longboard Pharmaceuticals Inc Funding & Investors

San Diego, CA

Longboard Pharmaceuticals delivers medicines with optimized pharmacology and pharmacokinetics to patients with rare neurological diseases. Its proprietary pipeline includes multiple programs with broad clinical utility. Longboard is evaluating LP352, a next-generation 5-HT2C agonist, in development for the potential treatment of developmental and epileptic encephalopathies, or DEEs. Longboard is also evaluating LP143, a centrally acting, full agonist of the cannabinoid type 2 receptor (CB2), and LP659, a centrally acting, next-generation, highly selective S1P receptor modulator.

longboardpharma.com

Total Amount Raised: $1,596,968

Longboard Pharmaceuticals Inc Funding Rounds

  • Post Ipo Equity

    $1,072,300

  • Post Ipo Debt

    $350,000

  • Post Ipo Debt

    $174,668

  • IPO

    Unknown

Funding info provided by Diffbot.